跳到正文
PR Newswire Health·· 2 小时前AI 评分5

Artivion 将参加两场投资者会议

Artivion to Participate in Upcoming Investor Conferences

AI 导读

Artivion 宣布将参加两场投资者会议,管理层于 11 月 10 日在 Stifel 2026 Healthcare Conference 演讲,并于 11 月 11 日出席第 20 届 Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum。

正文 · 原文

, /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.

Artivion's management team will present at the upcoming Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at the Lotte New York Palace Hotel. The Company's presentation is scheduled to begin at 11:20 a.m. ET. The management team will also present at the upcoming 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on Wednesday, November 11, 2026 at the Westin New York Grand Central Hotel. The Company's presentation is scheduled to begin at 8:00 a.m. ET.

A live webcast of both presentations can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcasts will be available for 90 days on the same website. 

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

Contacts:

Artivion

Gilmartin Group LLC

Lance A. Berry

Brian Johnston

Executive Vice President,

Phone: 332-895-3222

Chief Operating Officer &

[email protected]

Chief Financial Officer


Phone: 770-419-3355


SOURCE Artivion, Inc.

来源:PR Newswire Health · prnewswire.com

AI 摘要声明:站内标题、摘要与推荐理由由模型基于公开来源生成,属机器生成内容,非原文;本页内容仅供医药行业信息参考,不构成医疗建议、诊断或用药依据。